Brief: Rallybio Reports Positive Data In Clinical Program For Prevention Of FNAIT

Rallybio

01/12/2021 12:29

Dec 1 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO REPORTS POSITIVE DATA IN ITS CLINICAL PROGRAM FOR
THE
PREVENTION OF FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
(FNAIT)
    * RALLYBIO CORP- ANNOUNCED DATA FROM ITS ONGOING PHASE 1/2
STUDY
OF RLYB211 SHOWING SIGNIFICANT BENEFIT OVER PLACEBO
    * RALLYBIO CORP-  RLYB211 DEMONSTRATES ABILITY TO RAPIDLY
AND
SAFELY ELIMINATE HPA-1A MISMATCHED PLATELETS UP TO 7 DAYS AFTER
ADMINISTRATION
    * RALLYBIO CORP- DATA FROM PHASE 1/2 RLYB212 TRIAL ARE
ANTICIPATED
MID-YEAR 2022
    * RALLYBIO CORP- RESULTS FROM PHASE 1/2 STUDY OF RLYB211
COHORT 1B
SHOWED ACCEPTABLE SAFETY AND TOLERABILITY WITH NO SERIOUS
ADVERSE EVENTS
    * RALLYBIO - RLYB211 DATA SHOWS TREATMENT CAPACITY OF
ANTI-HPA-1A
ANTIBODIES TO CAUSE FAST, COMPLETE ELIMINATION OF MISMATCHED
PLATELETS IN VOLUNTEERS

Source text for Eikon:  ID:nBw7dsdBra 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))